Background
Familial adenomatous polyposis (FAP) is the most common adenomatous polyposis syndrome. It is an autosomal dominant inherited disorder characterized by the early onset of hundreds to thousands of adenomatous polyps throughout the colon. If left untreated, all patients with this syndrome develop colon cancer by age 35-40 years. In addition, an increased risk exists for the development of other malignancies. See the image below.
Colectomy specimen obtained from a patient with familial adenomatous polyposis. Note the presence of numerous synchronous adenomatous polyps lining the luminal surface. The genetic defect in FAP is a germline mutation in the adenomatous polyposis coli (APC) gene. Syndromes once thought to be distinct from FAP are now recognized to be, in reality, part of the phenotypic spectrum of FAP.
Syndromes with a germline mutation in the APC gene include FAP, Gardner syndrome, some families with Turcot syndrome, and attenuated adenomatous polyposis coli (AAPC). Gardner syndrome is characterized by colonic polyposis typical of FAP, along with osteomas (bony growth most commonly on the skull and the mandible), dental abnormalities, and soft tissue tumors. Turcot syndrome is characterized by colonic polyposis typical of FAP, along with central nervous system tumors (medulloblastoma). AAPC is characterized by fewer colonic polyps (average number of polyps, 30-35) as compared to classic FAP. The polyps also tend to develop at a later age (average age, 36 y), and they tend to involve the proximal colonic area.
In considering the spectrum of polyposis syndromes, patients with multiple adenomatous polyps most likely have FAP (or one of its variants), AAPC, or MYH-associated polyposis (MAP). If a patient with a suspected polyposis syndrome undergoes genetic testing and does not have an APC gene mutation, MYH gene testing should be performed to assess for MAP, as 10-20% of patients who do not have an APC gene mutation have biallelic MYH gene mutations.[1]
The phenotype of MAP is often indistinguishable from FAP or AAPC, with patients having usually 10-100 polyps but sometimes more than 100. The age of onset of MAP is usually in patients older than 45 years, and patients often present symptomatically, with colorectal carcinoma commonly found at the time of diagnosis. This is in part because there is usually no family history given the autosomal recessive inheritance pattern of MAP. Duodenal polyps can be found in up to one fifth of patients.[2] There is no increased risk of other types of cancers associated with this syndrome.
Pathophysiology
The APC gene is a tumor suppressor gene that is located on band 5q21. Its function is not completely understood but has been shown to play a part in metaphase chromosome alignment.[3] Normal APC protein promotes apoptosis in colonic cells. Its most important function may be to sequester the growth stimulatory effects of b-catenin, a protein that transcriptionally activates growth-associated genes in conjunction with tissue-coding factors. Mutations of the APC gene result in a truncated/nonfunctional protein.
The resultant loss of APC function prevents apoptosis and allows b-catenin to accumulate intracellularly and to stimulate cell growth with the consequent development of adenomas. As the clonal expansion of cells that lack APC function occurs, their rapid growth increases the possibility for other growth-advantageous genetic events to occur. This causes alterations in the expression of a variety of genes, thereby affecting the proliferation, differentiation, migration, and apoptosis of cells.
Ultimately, enough genetic events happen that allow the adenomatous polyps to become malignant in patients with FAP. This process is similar to that which occurs in sporadic adenomas. As a result, APC is considered the gatekeeper of colonic neoplasia. Its mutation/inactivation is the initial step in the development of colorectal cancer in patients with FAP.
Germline (ie, inherited) mutations of the APC gene, as is the case with FAP, result in cells containing 1 mutated copy and 1 normal copy of the gene. Patients inherit one mutated APC allele from an affected parent, and adenomas develop as the second allele from the unaffected parent becomes mutated or lost. Consequently, every colonic epithelial cell in patients with FAP has 1 mutated APC allele. Inactivation of the remaining normal copy of the APC gene, by deletion or mutation, completely removes the tumor suppressive function of APC, thus initiating the growth of adenomatous polyps. Inactivation of the second APC allele occurs frequently in the colon, resulting in the development of numerous adenomas.
A retrospective study of outcomes in 492 patients with polyposis found that age at polyposis onset and years of survival differed significantly by genotype, although age of onset of colorectal cancer did not.[4] Patients with a mutation in APC 0-178 or 312-412 developed polyposis later and survived longer, whereas patients with mutations in APC 1249-1549 developed polyposis earlier and did not survive as long.
Epidemiology
Frequency
United States
Estimates vary from 1 case in 6,850 persons to 1 case in 31,250 persons.
International
The frequency is constant worldwide.
Mortality/Morbidity
- The principal cause of mortality is colorectal cancer, which develops in all patients unless they are treated. The mean age at which colorectal cancer develops in patients with classic FAP is 39 years. Patients with adenomatous polyposis itself often are asymptomatic.
- The second reported lethal complication of FAP is diffuse mesenteric fibromatosis and is referred to as a desmoid tumor. It involves intra-abdominal organs and vessels, causing gastrointestinal obstruction and constriction of veins, arteries, and ureters. Desmoid tumors are reported in 4-32% of patients. Even after the appropriate surgical treatment of FAP, 20% of patients may develop desmoid tumors after colectomy. Studies have not found a correlation between specific APC mutation sites and desmoid tumor development.[5] Risk factors include a positive family history. The mortality from these tumors is 10-50%. The second most common malignancy in patients with FAP is adenocarcinoma of the duodenum and the papilla of Vater. It affects as many as 12% of patients.
- Rarer cancers associated with FAP include medulloblastomas (Turcot syndrome), hepatoblastoma, thyroid cancer, gastric cancer, pancreatic cancer, and adrenal cancer.[6]
Race
- FAP has been described in all races.
Sex
- The male-to-female ratio is 1:1.
Age
- The average age of onset of polyposis in FAP is 16 years.
- The average age of onset for colorectal cancer is 39 years.
- The average age of onset for polyps in AAPC is 36 years, and the average age of onset for cancer in AAPC is 54 years. These patients have fewer polyps (approximately 30 polyps) compared to patients with FAP.
Schulmann K, Pox C, Tannapfel A, Schmiegel W. The patient with multiple intestinal polyps. Best Practice & Research Clinical Gastroenterology [serial online]. June 2007;21(3):409-426. Available from: Science Direct. Accessed June 2, 2008. Available at http://www.sciencedirect.com.
Dekker E, Boparai KS, Poley JW, Mathus-Vliegen EM, Offerhaus GJ, Kuipers EJ, et al. High resolution endoscopy and the additional value of chromoendoscopy in the evaluation of duodenal adenomatosis in patients with familial adenomatous polyposis. Endoscopy. Aug 2009;41(8):666-9. [Medline].
Zhang J, Ahmad S, Mao Y. BubR1 and APC/EB1 cooperate to maintain metaphase chromosome alignment. J Cell Biol. Aug 27 2007;178(5):773-84. [Medline].
Newton K, Mallinson E, Bowen J, et al. Genotype-phenotype correlation in colorectal polyposis. Clin Genet. Jun 23 2011;[Medline].
Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A, et al. Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. Feb 2008;6(2):215-9. [Medline].
Will OC, Hansmann A, Phillips RK, Palazzo FF, Meeran K, Marshall M, et al. Adrenal incidentaloma in familial adenomatous polyposis: a long-term follow-up study and schema for management. Dis Colon Rectum. Sep 2009;52(9):1637-44. [Medline].
Ponti G, Losi L, Pellacani G, Rossi GB, Presutti L, Mattioli F, et al. Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). Applied Immunohistochemistry & Molecular Morphology [serial online]. January 25, 2008;Available from: Pubmed. Accessed March 15, 2008. Available at http://www.appliedimmunohist.com/.
Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol. Feb 2008;6(2):180-5. [Medline].
Wachsmannova-Matelova L, Stevurkova V, Adamcikova Z, Holec V, Zajac V. Different phenotype manifestation of familial adenomatous polyposis in families with APC mutation at codon 1309. Neoplasma. 2009;56(6):486-9. [Medline].
Duncan RE, Gillam L, Savulescu J, Williamson R, Rogers JG, Delatycki MB. The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis. Fam Cancer. Sep 17 2009;[Medline].
Douma KF, Bleiker EM, Aaronson NK, Cats A, Gerritsma MA, Gundy CM, et al. Long-term compliance with endoscopic surveillance advice for familial adenomatous polyposis (FAP). Colorectal Dis. Jul 10 2009;[Medline].
Friederich P, van Heumen BW, Nagtegaal ID, et al. Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis. Virchows Arch. Sep 2007;451(3):659-67. [Medline]. [Full Text].
Iaquinto G, Fornasarig M, Quaia M, et al. Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis. Gastrointest Endosc. Jan 2008;67(1):61-7. [Medline].
Johnson MD, Mackey R, Brown N, et al. Outcome based on management for duodenal adenomas: sporadic versus familial disease. J Gastrointest Surg. Nov 24 2009;[Medline].
Bresalier RS. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 2006;2759-2810.
Brosens LA, Keller JJ, Offerhaus GJ, et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut. Jul 2005;54(7):1034-43. [Medline].
Burke CA, Beck GJ, Church JM, et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc. Mar 1999;49(3 Pt 1):358-64. [Medline].
Burt R, Neklason DW. Genetic testing for inherited colon cancer. Gastroenterology. May 2005;128(6):1696-716. [Medline].
Bussey HJR. Genetic and epidemiological features of familial polyposis coli. In: Bussey HJR, ed. Familial Polyposis Coli. Baltimore, Md: Johns Hopkins University Press; 1975:9-17.
Doxey BW, Kuwada SK, Burt RW. Inherited polyposis syndromes: molecular mechanisms, clinicopathology, and genetic testing. Clin Gastroenterol Hepatol. Jul 2005;3(7):633-41. [Medline].
Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. Feb 2006;101(2):385-98. [Medline].
Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med. Mar 20 1997;336(12):823-7. [Medline].
Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. May 6 1993;328(18):1313-6. [Medline].
Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. Apr 4 2002;346(14):1054-9. [Medline].
Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. Feb 20 2002;94(4):252-66. [Medline].
Print
